Navigation Links
U of A medical researchers ID genetic marker for sporadic breast cancer
Date:5/28/2013

Medical researchers at the University of Alberta have pinpointed a genetic marker for sporadic breast cancer one of a handful identified to date in Caucasians.

Researchers have identified many genetic markers for familial breast cancers, but not for sporadic breast cancer which accounts for 80 per cent of all cases. Sambasivarao Damaraju, a professor with the Faculty of Medicine & Dentistry and a researcher at the Cross Cancer Institute, worked with his team to scan the DNA of about 7,200 Alberta women, including those who have had sporadic breast cancer and those who have not had cancer. Their genomes were scanned from DNA isolated from blood.

The results? Women who had sporadic breast cancer frequently had a genetic marker on chromosome 4 a marker that has never been associated with familial breast cancer cases.

"The frequency of this marker occurring was statistically significant," says Damaraju, who works in the Department of Laboratory Medicine & Pathology. "Genetic factors that predispose women to breast cancer is a subject of intense investigation in the research world. While 60 to 70 genetic risk factors have been identified for familial breast cancer, we don't know much about the genetic risk factors for sporadic breast cancer. So this finding is exciting, and shows us more research is needed in this area."

The team's findings were recently published in the peer-reviewed journal, PLoS One. Damaraju noted the team, which included co-author John Mackey and PhD student Yadav Sapkota, was multi-disciplinary, including basic scientists, medical oncologists, biostatisticians and epidemiologists. He also acknowledged the initial contributions to this work from previous trainees, Malinee Sridharan and Badan S. Sehrawat. Overall, he collaborated with colleagues from the U of A's School of Public Health, the Department of Oncology, and the Department of Agricultural, Food and Nutritional Sciences, as well as colleagues from the Cross Cancer Institute and Alberta Health Services.

Damaraju and his team are continuing their work in this very young field (the first genetic marker for breast cancer predisposition was reported in 2007). He says more research is needed to identify genetic markers for sporadic breast cancer, but that large scale screening to identify those at risk is still years away.

Lifestyle factors account for two-thirds of the risk associated with breast cancer, while the remaining one-third of the risk is attributed to genetics, Damaraju noted.

The research was funded by the Alberta Cancer Foundation and the Canadian Breast Cancer Foundation Prairies/NWT region.

"We are pleased to see donor dollars having a direct impact on outcomes that are important to Albertans in this case identifying a genetic marker of a specific breast cancer may lead to earlier detection and improved treatment options," says Myka Osinchuk, CEO of the Alberta Cancer Foundation. "For years, the Alberta Cancer Foundation has invested in the 'biobank' that has given this research team access to the blood and tissue samples used in this study, and we recently confirmed our support with more funding. It is exciting to see how this comprehensive collection of tumour and tissue samples is starting to provide answers to key clinical questions."

Tracy Sopkow, VP, Cause Related Programs with the Canadian Breast Cancer Foundation Prairies/NWT Region, added: "Our organization believes in supporting innovative research that has the potential to make a real, tangible difference. We're proud to support Dr. Damaraju and his team in their quest to identify genetic markers for sporadic breast cancer because the knowledge gained has the potential to change the future for thousands of women."


'/>"/>

Contact: Raquel Maurier
rmaurier@ualberta.ca
780-492-5986
University of Alberta Faculty of Medicine & Dentistry
Source:Eurekalert

Related biology news :

1. Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings
2. Miniature pressure sensors for medical touch
3. Research!America says house funding levels for FY13 could undermine medical progress
4. Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship
5. Medical device, health professionals attend first national conference on value-driven engineering
6. Ultrasensitive biosensor promising for medical diagnostics
7. UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure
8. Tufts Medical Center researchers finds marker in premies saliva predicts readiness to feed by mouth
9. CDS Monarch Deploys DigitalPersona Strong Authentication Solutions for Secure Access to Electronic Medical Records
10. Nuisance seaweed found to produce compounds with biomedical potential
11. MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
Breaking Biology Technology: